Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SRRK | US
0.07
0.95%
Healthcare
Biotechnology
30/06/2024
04/10/2024
7.42
7.17
7.43
7.11
Scholar Rock Holding Corporation a biopharmaceutical company focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181 which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases including neuromuscular disorders cancer fibrosis and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge Massachusetts.
View LessPrice Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
87.2%1 month
76.7%3 months
63.8%6 months
61.6%-
-
5.23
0.51
0.30
-2.08
8.22
-
-207.14M
593.84M
593.84M
-
-
-
-100.00
-121.29
28.15
44.92
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.93
Range1M
2.93
Range3M
3.08
Rel. volume
0.70
Price X volume
4.81M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Humacyte Inc | HUMA | Biotechnology | 5.44 | 650.86M | -4.39% | n/a | -63.37% |
Arcturus Therapeutics Ltd | ARCT | Biotechnology | 23.88 | 645.77M | -6.28% | n/a | 11.94% |
Entrada Therapeutics Inc. Common Stock | TRDA | Biotechnology | 17.07 | 635.00M | 4.79% | 5.45 | 14.99% |
Y-Mabs Therapeutics Inc - Ordinary Shares | YMAB | Biotechnology | 14.16 | 631.11M | 0.57% | n/a | 1.34% |
Savara Inc | SVRA | Biotechnology | 3.82 | 628.78M | -2.05% | n/a | 26.18% |
Stoke Therapeutics Inc | STOK | Biotechnology | 11.79 | 620.72M | -3.28% | n/a | 2.40% |
Lexicon Pharmaceuticals Inc | LXRX | Biotechnology | 1.69 | 610.92M | 4.97% | n/a | 44.04% |
Oculis Holding AG Ordinary shares | OCS | Biotechnology | 13.2 | 551.04M | 8.20% | n/a | 1.19% |
Pharming Group N.V. | PHAR | Biotechnology | 8.04 | 545.40M | -0.74% | n/a | 63.43% |
Revance Therapeutics Inc | RVNC | Biotechnology | 5.22 | 543.82M | 0.58% | n/a | -378.95% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.08 | 0.76 | Cheaper |
Ent. to Revenue | 8.22 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 5.23 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 63.76 | 74.67 | Par |
Debt to Equity | 0.51 | -1.82 | Expensive |
Debt to Assets | 0.30 | 0.26 | Par |
Market Cap | 593.84M | 3.73B | Emerging |